SBC Medical Group (NASDAQ:SBC) & Co-Diagnostics (NASDAQ:CODX) Head-To-Head Contrast

SBC Medical Group (NASDAQ:SBCGet Free Report) and Co-Diagnostics (NASDAQ:CODXGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Earnings & Valuation

This table compares SBC Medical Group and Co-Diagnostics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SBC Medical Group $173.61 million 1.71 $50.99 million $0.39 7.41
Co-Diagnostics $620,000.00 11.44 -$46.90 million ($18.92) -0.10

SBC Medical Group has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SBC Medical Group and Co-Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SBC Medical Group 24.09% 15.90% 11.61%
Co-Diagnostics -6,760.63% -164.92% -141.15%

Volatility & Risk

SBC Medical Group has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for SBC Medical Group and Co-Diagnostics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SBC Medical Group 0 1 2 0 2.67
Co-Diagnostics 1 2 1 0 2.00

SBC Medical Group presently has a consensus price target of $8.50, suggesting a potential upside of 194.12%. Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 3,326.40%. Given Co-Diagnostics’ higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than SBC Medical Group.

Insider and Institutional Ownership

60.8% of SBC Medical Group shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 89.5% of SBC Medical Group shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

SBC Medical Group beats Co-Diagnostics on 11 of the 14 factors compared between the two stocks.

About SBC Medical Group

(Get Free Report)

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.

About Co-Diagnostics

(Get Free Report)

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Receive News & Ratings for SBC Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SBC Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.